XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q2)Dec 31, 2024 | (Q1)Sep 30, 2024 | (FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -9.36%674M | -1.63%585.9M | -3.57%2.7B | 0.20%643.5M | -4.15%717.7M | -6.19%743.6M | -3.39%595.6M | -21.83%2.8B | -5.38%642.2M | -22.35%748.8M |
Operating revenue | -9.36%674M | -1.63%585.9M | -3.57%2.7B | 0.20%643.5M | -4.15%717.7M | -6.19%743.6M | -3.39%595.6M | -21.83%2.8B | -5.38%642.2M | -22.35%748.8M |
Cost of revenue | -19.95%355.6M | -9.00%282.2M | -20.39%1.49B | -24.82%331.6M | -14.77%408M | -20.34%444.2M | -22.34%310.1M | -34.92%1.88B | -37.74%441.1M | -38.64%478.7M |
Gross profit | 6.35%318.4M | 6.45%303.8M | 30.64%1.21B | 55.15%312M | 14.62%309.7M | 27.40%299.4M | 31.40%285.4M | 32.23%923.5M | 774.83%201.1M | 46.69%270.2M |
Operating expense | -26.67%344.3M | -30.84%259.9M | -9.77%1.61B | -1.40%367.5M | -17.67%399.2M | -7.51%469.5M | -10.82%375.8M | -33.32%1.79B | -54.14%372.7M | -11.37%484.9M |
Selling and administrative expenses | -27.45%274.9M | -32.21%201.4M | -9.08%1.26B | 3.29%251.2M | -19.94%323.3M | -7.52%378.9M | -10.57%297.1M | -27.17%1.39B | -22.77%243.2M | -14.09%403.8M |
-Selling and marketing expense | -33.90%148.2M | -43.90%81.9M | 2.98%635.5M | -16.78%88.8M | 10.16%170.3M | 3.27%224.2M | 5.26%146M | -37.62%617.1M | -16.96%106.7M | -32.10%154.6M |
-General and administrative expense | -18.10%126.7M | -20.91%119.5M | -18.72%627.3M | 18.97%162.4M | -38.60%153M | -19.68%154.7M | -21.91%151.1M | -15.90%771.8M | -26.77%136.5M | 2.85%249.2M |
Research and development costs | -24.53%60.3M | -25.67%58.5M | -4.27%304.8M | -3.74%69.4M | -1.79%76.8M | -0.13%79.9M | -10.67%78.7M | -11.43%318.4M | -15.08%72.1M | 1.43%78.2M |
Depreciation amortization depletion | -25.41%9.1M | ---- | -17.94%47.1M | ---- | ---- | --12.2M | ---- | -23.77%57.4M | ---- | ---- |
-Depreciation and amortization | -25.41%9.1M | ---- | -17.94%47.1M | ---- | ---- | --12.2M | ---- | -23.77%57.4M | ---- | ---- |
Other operating expenses | ---- | ---- | -111.82%-2.6M | ---200K | -131.03%-900K | -108.38%-1.5M | ---- | -93.48%22M | --0 | --2.9M |
Operating profit | 84.77%-25.9M | 148.56%43.9M | 53.01%-405.6M | 67.66%-55.5M | 58.31%-89.5M | 37.60%-170.1M | 55.73%-90.4M | 56.43%-863.2M | 79.63%-171.6M | 40.84%-214.7M |
Net non-operating interest income expense | -39.38%-26.9M | -45.21%-27.3M | -9.48%-77.4M | -12.30%-21M | 1.60%-18.4M | -17.68%-19.3M | -11.24%-18.8M | -73.71%-70.7M | -22.22%-18.7M | -110.11%-18.7M |
Non-operating interest income | -8.33%7.7M | -3.57%8.1M | 32.95%35.1M | 2.30%8.9M | 17.72%9.3M | 44.83%8.4M | 110.00%8.4M | 1,047.83%26.4M | 625.00%8.7M | 3,850.00%7.9M |
Non-operating interest expense | 24.91%34.6M | 30.15%35.4M | 15.86%112.5M | 9.12%29.9M | 4.14%27.7M | 24.77%27.7M | 30.14%27.2M | 125.81%97.1M | 66.06%27.4M | 192.31%26.6M |
Other net income (expense) | -424.66%-38.3M | 66.33%-16.6M | 78.67%-69.1M | 190.22%46.1M | -40.10%-58.7M | 83.60%-7.3M | 73.58%-49.3M | 58.80%-324M | 86.73%-51.1M | 89.07%-41.9M |
Gain on sale of security | -292.71%-18.5M | 289.74%14.8M | ---- | ---- | -123.08%-2.1M | -18.64%9.6M | 54.12%-7.8M | 122.01%7M | 124.41%3.1M | 179.13%9.1M |
Special income (charges) | -17.65%-20M | 25.12%-31.3M | 79.10%-69.8M | 184.47%45.7M | -10.12%-56.6M | 71.04%-17M | 75.38%-41.8M | 55.66%-333.9M | 85.39%-54.1M | 86.22%-51.4M |
-Less:Restructuring and merger&acquisition | -75.37%3.3M | -83.71%2.9M | -65.10%66.1M | -112.56%-2.7M | 213.33%37.6M | -72.65%13.4M | -83.35%17.8M | 4.81%189.4M | -3.15%21.5M | -92.43%12M |
-Less:Impairment of capital assets | ---- | -79.58%4.9M | -60.35%57.3M | ---- | ---- | ---- | -61.84%24M | -74.76%144.5M | ---- | ---- |
-Less:Other special charges | ---- | --23.5M | ---53.6M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-Write off | 363.89%16.7M | ---- | ---- | ---- | -51.78%19M | -62.89%3.6M | ---- | ---- | ---- | --39.4M |
Other non- operating income (expenses) | 100.00%200K | -133.33%-100K | -75.86%700K | 300.00%200K | ---- | -95.83%100K | 50.00%300K | 293.33%2.9M | 95.45%-100K | -66.67%400K |
Income before tax | 53.61%-91.2M | 0 | 56.11%-552.1M | 87.46%-30.3M | 39.43%-166.7M | 41.05%-196.6M | 61.12%-158.5M | 55.20%-1.26B | 80.56%-241.6M | 63.55%-275.2M |
Income tax | 141.18%700K | 0.00%800K | -105.41%-200K | -50.00%100K | -25.00%600K | -189.47%-1.7M | 0.00%800K | -81.12%3.7M | -98.35%200K | -61.90%800K |
Net income | 52.85%-91.9M | 99.50%-800K | 56.26%-551.9M | 87.43%-30.4M | 39.38%-167.3M | 41.89%-194.9M | 61.00%-159.3M | 55.38%-1.26B | 80.74%-241.8M | 63.55%-276M |
Net income continuous Operations | 52.85%-91.9M | 99.50%-800K | 56.26%-551.9M | 87.43%-30.4M | 39.38%-167.3M | 41.89%-194.9M | 61.00%-159.3M | 55.38%-1.26B | 80.74%-241.8M | 63.55%-276M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 52.80%-92M | 99.44%-900K | 56.26%-551.9M | 87.39%-30.5M | 39.36%-167.3M | 41.89%-194.9M | 61.00%-159.3M | 55.38%-1.26B | 80.74%-241.8M | 63.56%-275.9M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 52.80%-92M | 99.44%-900K | 56.26%-551.9M | 87.39%-30.5M | 39.36%-167.3M | 41.89%-194.9M | 61.00%-159.3M | 55.38%-1.26B | 80.74%-241.8M | 63.56%-275.9M |
Basic earnings per share | 55.56%-0.24 | 99.46%-0.0024 | 58.52%-1.51 | 88.24%-0.08 | 43.04%-0.45 | 44.90%-0.54 | 63.33%-0.44 | 58.49%-3.64 | 81.52%-0.68 | 65.20%-0.79 |
Diluted earnings per share | 55.56%-0.24 | 99.46%-0.0024 | 58.52%-1.51 | 88.24%-0.08 | 43.04%-0.45 | 44.90%-0.54 | 63.33%-0.44 | 58.49%-3.64 | 81.52%-0.68 | 65.20%-0.79 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |